ADVENTRX Pharmaceuticals Inc (Anx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: estatemakr who wrote (98)	5/22/2007 4:29:28 PM
From: Keith Feral	Read Replies (1) of 418

AMGN is not going to make a pass at Cofactor for the simple reason that it renders all of their bone marrow support drugs worthless in chemotherapy. AMGN will continue to protect it's own interests. JNJ is a totally different situation. They sell epogen in Europe and the also have an interest in procrit. However, these drugs are a small part of the overall revenue base. They could swiftly purchase a drug like cofactor for $1 or $2 billion, and add $5 billion in market cap. I read the notes from Dawson James to confirm the comments on briefing.com were new comments on 5/21. Bottom line, cofactor eliminates anemia and neutropenia, which eliminates the demand for drugs like epogen or other bone marrow support drugs. I remember when QCOM was $50 and everyone wondered why NOK did not buy them out. LU, NT, and alot of other companies were flushed down the toilet when CDMA and WCDMA were named as 3G technologies. I expect Cofactor to have an equally disruptive impact for some of the big cap biotechs like AMGN. The big ones are always susceptible to gravity. Arrogance, greed, and complacency are impossible to avoid.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next